Group 1 - The core viewpoint of the news is that Guoen Technology (国恩科技) is preparing for its IPO in the Hong Kong market, with a strong foundation and significant fundraising expectations [2][4] - Guoen Technology plans to globally issue approximately 30 million H-shares, with 3 million shares allocated for public offering in Hong Kong and 27 million shares for international offering [2] - The expected net fundraising amount is approximately HKD 1.058 billion, with funds allocated for expanding production capacity in Thailand and China, as well as for operational purposes [2][4] Group 2 - Guoen Technology specializes in new chemical materials and collagen products, serving the chemical and health industries, focusing on R&D, production, and sales [4] - The company ranks second in the organic polymer modification and composite materials industry in China by sales revenue, with a market share of 2.5%, and is the largest producer of polystyrene in China [4] - In the health sector, Guoen Technology's subsidiary, Dongbao Biological, has established a complete layout from collagen raw materials to end products, becoming a comprehensive group in the health segment [4] Group 3 - For the fiscal years 2022 to 2024, Guoen Technology's revenues were RMB 13.406 billion, RMB 17.439 billion, and RMB 19.188 billion, with corresponding profits of RMB 0.724 billion, RMB 0.540 billion, and RMB 0.721 billion [5] - The company has shown solid performance in its financial results, indicating a stable growth trajectory [5]